ClinicalTrials.gg
RecruitingNCT06379646Updated Oct 22, 2026

An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease

An interventional study of YTS109 in Systemic Lupus Erythematosus, Systemic Sclerosis and Inflammatory Myopathy, sponsored by China Immunotech (Beijing) Biotechnology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by China Immunotech (Beijing) Biotechnology Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Updated Oct 22, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
229th of 245
6 · median 36
Started
2024
with 42 others
No phase
32 of 266
21 open now
Primary completion
2027-04
later than 93 of 190 live
Registered
119th of 266
by date
Lead sponsor
6 of 266
China Immunotech (Beijing) Biotechnology Co., Ltd.

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 229th largest by planned enrollment of the 245 interventional ones that give a count, is one of 43 that started in 2024, is one of 32 with no phase, reaches primary completion later than 93 of the 190 other live ones, and was the 119th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

An exploratory clinical study of the safety and efficacy of YTS109 cell injection in subjects with recurrent/refractory autoimmune disease

Read the detailed description

This study is a prospective exploratory clinical trial in subjects with recurrent/refractory autoimmune disease. The objective is to evaluate the safety, initial efficacy and PK/PD characteristics of YTS109 cells in the treatment of recurrent/refractory autoimmune diseases.

03

Conditions studied

  • Systemic Lupus Erythematosus
  • Systemic Sclerosis
  • Inflammatory Myopathy
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
  • Antiphospholipid Syndrome
  • Sjogren's Syndrome
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ranges from 18 to 65 years old (including threshold), regardless of gender.
  2. Positive expression of CD19 on peripheral blood B cells determined by flow cytometry.
  3. The functions of important organs meet the following requirements:

    1. Bone marrow hematopoietic function needs to meet: ≥1×109/L; ≥60g/L;
    2. Liver function: ≤3×; AST≤3×ULN; ≤1.5×ULN;
    3. Renal function: (CrCl) ≥30 ml/minute;
    4. Coagulation function: International standardized ratio () ≤1.5×ULN, prothrombin time (PT) ≤1.5×ULN;
    5. Heart function: good hemodynamic stability;
  4. Female subjects with fertility and male subjects whose partners are women of childbearing age are required to use medically approved or abstinence during the study treatment period and at least 6 months after the end ofthe study treatment period; Female subjects of childbearing age tested negative for serum HCG within 7 days before enrollment in the study and were not in lactation.
  5. Voluntarily participate in this clinical study, sign an form, have good compliance, and cooperate with follow-up.

Specific inclusion criteria:

Recurrent systemic lupus erythematosus

  1. Complies with the classification standards of the 2019 European Union Against Rheumatology/American Society of Rheumatology (EULAR/ACR) SLE;
  2. Disease activity score SELENA SLEDAI≥6 with at least one Injima Lupus Assessment Group Index (BILAG-2004) category A (severe presentation) or two Category B (moderate presentation) organ scores, or both; Or disease activity score SELENA SLEDAI score ≥8;
  3. Definition of relapse refractory: conventional treatment remains ineffective for more than 6 months or disease activity occurs again after remission. Conventional treatment is defined as the use of and cyclophosphamide, and any of the following immunomodulators: antimalarials, azathioprine, mortemycophanate, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab and telitacicept.

Recurrent refractory sjogren's syndrome

  1. Meet the 2002 AECG criteria for primary Sjogren's syndrome or the 2016 ACR/EULAR classification criteria;
  2. Disease activity ESSDAI≥6;
  3. Positive anti-SSA /Ro antibody;
  4. Definition of relapse refractory: conventional treatment remains ineffective for more than 6 months or disease activity occurs again after remission. Conventional treatment is defined as the use of glucocorticoids and cyclophosphamide, and any of the following immunomodulators: antimalarials, azathioprine, mortemycophanate, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab and telitacicept.

Relapsing refractory/progressive diffuse systemic sclerosis

  1. Meet the 2013 ACR classification criteria for systemic sclerosis;
  2. Positive antibodies related to systemic sclerosis;
  3. Diffuse sclerosis of the skin or active interstitial pneumonia (HRCT suggests ground glass exudation);
  4. Definition of relapse refractory: conventional treatment remains ineffective for more than 6 months or disease activity occurs again after remission. Conventional treatment is defined as the use of glucocorticoids and cyclophosphamide, and any of the following immunomodulators: antimalarials, azathioprine, mortemycophanate, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab and telitacicept
  5. Definition of progression: rapid skin progression (mRSS increase >25%); Or progression of lung disease (a 10% reduction in FVC, or a more than 5% reduction in FVC with a 15% reduction in DLCO).
  6. Note: Articles 4 and 5 satisfy one or the other.

Recurrent refractory/progressive inflammatory myopathy:

  1. Meet the 2017 EULAR/ACR classification criteria for inflammatory myopathy (including DM, PM, ASS and NM);
  2. Positive myositis antibody;
  3. Patients with muscle involvement had an MMT-8 score of less than 142 and abnormal findings on at least two of the following five core measures (PhGA, PtGA, extra-muscular disease activity score ≥2; HAQ total score ≥0.25; Muscle enzyme levels were 1.5 times the upper limit of the normal range); Or MMT-8≥142 with active interstitial lung disease (HRCT suggests ground glass exudation);
  4. Definition of relapse refractory: conventional treatment remains ineffective for more than 6 months or disease activity occurs again after remission. Conventional treatment is defined as the use of glucocorticoids and cyclophosphamide, and any of the following immunomodulators: antimalarials, azathioprine, mortemycophanate, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab and telitacicept
  5. Definition of progressive: myositis aggravation or rapid progression of interstitial pneumonia.

Note: Clauses 4 and 5 satisfy one or the other.

Recurrent/refractory ANCA-associated vasculitis:

  1. Meet the 2022ACR/EULAR diagnostic criteria for ANCA vasculitis, including microscopic polyvasculitis, granulomatous polyvasculitis, and eosinophilic granulomatous polyvasculitis.
  2. Anca-associated antibody positive (MPO-ANCA or PR3-ANCA positive);
  3. Birmingham vasculitis activity score (BVAS) ≥15 points (total 63 points), indicating vasculitis disease activity;
  4. Definition of relapse refractory: conventional treatment remains ineffective for more than 6 months or disease activity occurs again after remission. Conventional treatment is defined as the use of glucocorticoids and cyclophosphamide, and any of the following immunomodulators: antimalarials, azathioprine, mortemycophanate, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab and telitacicept.

Recurrent refractory/catastrophic antiphospholipid syndrome:

  1. Meet the diagnostic criteria for primary antiphospholipid syndrome as revised in Sydney 2006;
  2. Positive titers of phospholipid antibodies (IgG/IgM of LA, B2GP1 or acL, more than two positive tests within 12 weeks);
  3. Definition of relapse resistance: standard therapy with warfarin anticoagulant or replacement vitamin K antagonists (i.e., maintenance of the INR required for treatment) or with standard therapeutic dose of low molecular weight heparin (LMWH), as well as treatment of recurrent thrombosis with past hormones and cyclophosphamide;
  4. Catastrophic antiphospholipid syndrome needs to meet the following four criteria: (1) involvement of three or more organs, systems and/or tissues; (2) Symptoms appear within 1 week; (3) confirmed obstruction of small blood vessels in at least one organ or tissue; (4) aPL was positive.

Note: Clauses 3 and 4 satisfy one or the other.

Exclusion criteria

Exclusion Criteria:

  1. People with severe drug allergy or allergic constitution;
  2. the presence or suspicion of fungal, bacterial, viral or other infections that cannot be controlled or require treatment;
  3. Subjects with central nervous system disorders (excluding pre-existing epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident, encephalitis, central nervous system vasculitis as a result of the disease);
  4. Patients with cardiac dysfunction;
  5. Subjects with congenital immunoglobulin deficiency;
  6. History of malignant tumor in recent five years;
  7. Subjects with end-stage renal failure;
  8. Subjects with surface antigen (HBsAg), hepatitis B core antibody (HBcAb) positive and peripheral blood HBV DNA titer higher than the upper limit of detection; virus (HCV) antibody positive and peripheral blood HCV RNA positive; (HIV) antibody positive; Syphilis positive;
  9. Mental illness and severe cognitive impairment;
  10. Participants who had participated in other clinical trials within 3 months before enrollment;
  11. The duration of use of that have therapeutic effects on the disease before enrollment was within five half-lives or biologics within four weeks;
  12. A woman who is pregnant or planning to become pregnant;
  13. The investigators believe that there are also subjects who could not be included in the study for other reasons.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    YTS109

    YTS109 cell injection

    Other: YTS109

Interventions

  • OtherYTS109

    Subjects will receive YTS109 Cell Injection(3E6STAR+T cell/kg) once in this study.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Safety assessments are conducted using the NCI-CTCAE version 5.0 standards.

    Time frame: 3 months for safety measurements during the treatment assessment period

  2. Efficacy outcomes for SLE

    SLE Response index 4(SR-4) response: Min/Max Value: Not specife: a decrease in score indicates improvement: hicher scores indicate worse outcome

    Time frame: 3 months for efficacy measurements during the treatment assessment period

  3. Efficacy outcomes for Sjogren's Syndrome

    Sjogren's tool for assessing response (STAR): Min/Max Value: Not specified: a decrease n score indicates improvement: higher scores indicate worse outcome

    Time frame: 3 months for efficacy measurements during the treatment assessment period

  4. Efficacy outcomes for Systemic Sclerosis

    ACR-CRISS score (CRISS score ≥0.6 improvement, \< 0.6 no improvement) and modified CRISS score (rCRISS score) (percentage of patients with at least 3 of the 5 core items of ACR-CRISS improved by a certain percentage (e.g. 25%, except FVC (5%))

    Time frame: 3 months for efficacy measurements during the treatment assessment period

  5. Efficacy outcomes for Inflammatory Myopathy

    Total lmprovement Score (TlS):Min/Max Value: Not specified; an increase in score indicates improvement, higher scores indicate better outcome

    Time frame: 3 months for efficacy measurements during the treatment assessment period

  6. Efficacy outcomes for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

    Birmincham vascultis activity score (BVAS) scoreMin/Max Value: 0 to 63: an increase in score indicates worsening condition: higher cores indicate: Worse Outcome

    Time frame: 3 months for efficacy measurements during the treatment assessment period

  7. Efficacy outcomes for Antiphospholipid Syndrome

    Evaluaton of new thromboss as an indicator of relapsed/refractory/catastrophic Antiphostholpid Syndrome higher scores lndicate worse outcome (indicates procression of thesyndrome).

    Time frame: 3 months for efficacy measurements during the treatment assessment period

Secondary outcomes

  1. Peak Plasma Concentration (Cmax) of YTS109

    To evaluate the metabolic characteristics of YTS109

    Time frame: 3 and 6 months

  2. Time to Peak (Tmax) of YTS109

    To evaluate the metabolic characteristics of YTS109

    Time frame: 3 and 6 months

  3. Area under the plasma concentration versus time curve (AUC) of YTS109

    To evaluate the metabolic characteristics of YTS109

    Time frame: 3 and 6 months

  4. PD parameters

    Changes in cytokines in peripheral blood

    Time frame: 3 and 6 months

  5. Efficacy outcomes for SLE

    SLE Response index 4(SR-4) response: Min/Max Value: Not specife: a decrease in score indicates improvement: hicher scores indicate worse outcome

    Time frame: 6 months for efficacy measurements during the treatment assessment period

  6. Efficacy outcomes for Sjogren's Syndrome

    Sjogren's tool for assessing response (STAR): Min/Max Value: Not specified: a decrease n score indicates improvement: higher scores indicate worse outcome

    Time frame: 6 months for efficacy measurements during the treatment assessment period

  7. Efficacy outcomes for Systemic Sclerosis

    ACR-CRISS score (CRISS score ≥0.6 improvement, \< 0.6 no improvement) and modified CRISS score (rCRISS score) (percentage of patients with at least 3 of the 5 core items of ACR-CRISS improved by a certain percentage (e.g. 25%, except FVC (5%))

    Time frame: 6 months for efficacy measurements during the treatment assessment period

  8. Efficacy outcomes for Inflammatory Myopathy

    Total lmprovement Score (TlS):Min/Max Value: Not specified; an increase in score indicates improvement, higher scores indicate better outcome

    Time frame: 6 months for efficacy measurements during the treatment assessment period

  9. Efficacy outcomes for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

    Birmincham vascultis activity score (BVAS) scoreMin/Max Value: 0 to 63: an increase in score indicates worsening condition: higher cores indicate: Worse Outcome

    Time frame: 6 months for efficacy measurements during the treatment assessment period

  10. Efficacy outcomes for Antiphospholipid Syndrome

    Evaluaton of new thromboss as an indicator of relapsed/refractory/catastrophic Antiphostholpid Syndrome higher scores lndicate worse outcome (indicates procression of thesyndrome).

    Time frame: 6 months for efficacy measurements during the treatment assessment period

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wang X, Zhang Y, Wang H, Wu X, He C, Lin S, Pang K, Li Y, Chen Y, Tang X, Liu X, Wang J, Ye S, Yan R, Guan T, Dai B, Lu J, He H, Lin L, Lu H, Li T, Zhou L, Ye L, Zhao J, Liu Y, Ta N, Wu J, Cai W, Wan Z, Zhang S, Sun R, Zhao X, Wang J, Lin Y, Ning B, Zhao Z, Tang X, Du J, Mao Z, He Y, Zheng H, Sun L, Lin X, Xu H. Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. 2025 Nov;31(11):3713-3724. doi: 10.1038/s41591-025-03899-x. Epub 2025 Aug 27. PubMed 40866583 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Apr 2027, 29 months after the start.

Of 130 interventional studies with no phase under Lupus Erythematosus, Systemic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 29 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Apr 2024 → Oct 2024, primary completion Apr 2025 → Apr 2027 and completion Apr 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2024
First posted
Apr 23, 2024
StartActual
Oct 24, 2024was Apr 2024
Primary completionEst.
Apr 21, 2027was Apr 2025
CompletionEst.
Apr 21, 2027was Apr 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Shanghai Changzheng Hospital · Shanghai, China
Show 1 removed
  • Shanghai Changzheng Hospital · Shanghai, China
Oct 22, 2026
Start date
Apr 24, 2024→Oct 24, 2024
Oct 22, 2026
Primary completion
Apr 21, 2025→Apr 21, 2027
Oct 22, 2026
Study completion
Apr 21, 2026→Apr 21, 2027
Oct 22, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40866583 ↗
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40866583 ↗
    1 site added, 1 site removed
    Show site
    • Shanghai Changzheng Hospital · Shanghai, China
    Show 1 removed
    • Shanghai Changzheng Hospital · Shanghai, China
    Start date Apr 24, 2024→Oct 24, 2024
    Primary completion Apr 21, 2025→Apr 21, 2027
    Study completion Apr 21, 2026→Apr 21, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06379646
Lead sponsor
China Immunotech (Beijing) Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Apr 23, 2024
Start date
Oct 24, 2024
Primary completion
Apr 21, 2027 (estimated)
Completion
Apr 21, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Huji Xu
Contact
xuhuji@smmu.edu.cn
8602181886999
Huji Xu, MD,Ph.D
principal investigator · Shanghai Changzheng Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion